PR97572

SINGAPORE, Aug. 26, 2022 /PRNewswire=KYODO JBN/ --

- Pfizer is ranked 1st in Australia/New Zealand region and overall 2nd in Asia

in its corporate reputation from a patient perspective

- Asian patient groups have placed the pharma industry 1st for corporate

reputation in Asia amongst other healthcare sectors

Pfizer has been ranked first in its Covid-19 response, patient centricity,

patient safety and bringing innovative, high-quality products amongst pharma

companies in Asia in the 'Corporate Reputation of Pharma' survey by patient

groups across the APAC region. Overall, the company is ranked second for its

corporate reputation across Asian countries and regions.

https://mma.prnewswire.com/media/1885793/Pfizer_Logo.jpg

Pfizer moved up in the survey rankings from 4th place to occupy the top ranking

from patient groups 'working' with Pfizer, representing a significant increase

in rankings in 2021 vs. 2020.

This survey, conducted by UK-based PatientView, measures various aspects of

pharma's performance at corporate reputation from a patient perspective.

Patient groups responding to this survey are working across therapeutic areas

and uniquely positioned to comment on the pharma industry's performance during

the pandemic.

Opinions from 300 patient groups from across Asia (Hong Kong, Taiwan, India,

Malaysia, Philippines, Australia, S.Korea, mainland China and others) were

collected on the performance of the pharmaceutical industry in 2021. They have

collectively been in communication with nearly 2.7 million Asian patients in

2021. A total of 31 pharmaceutical companies were assessed in the Asia edition

of this survey.

Asian patient groups familiar with and/or working with Pfizer assessed the

company to have significantly improved its scores across all indicators of

corporate reputation in 2021.

Pharma's performance at creating vaccines at speed in response to the Covid-19

pandemic convinced most of the respondents of the industry's and Pfizer's

effectiveness at both innovation and ability to deliver products that truly

benefit patients.

"Patients are our North Star. From the earliest stage of drug development to

the final approval and use of our medicines and vaccines, our purpose is

breakthroughs that change patients' lives. We work with, and for, patients,

advocates, and caregivers to meet the evolving needs of patients everywhere.

Colleagues across Pfizer collaborate with patients and patient advocates to

develop breakthrough treatments and innovative approaches to help address

patient challenges. These partnerships have helped to increase patient

engagement in research and development, diversify clinical trials, develop

patient-friendly educational materials and patient support programs, and

elevate priority policy and social impact issues. Patients are the focus of

everything we do. Everything we do is intended to help patients everywhere live

longer and healthier lives", said Mr. Anil Argilla, President, Emerging Markets

Asia, Pfizer Biopharmaceuticals Group, Pfizer Inc.

The results of the pharma corporate reputation survey (Asia) are available at:

https://www.patient-view.com/wp-content/uploads/2022/08/PATIENTVIEW-PRESS-RELEASE-CORP-REP-Asia-final.pdf.

About Pfizer: Breakthroughs That Change Patients' Lives

At Pfizer, we apply science and our global resources to bring therapies to

people that extend and significantly improve their lives. We strive to set the

standard for quality, safety and value in the discovery, development and

manufacture of health care products, including innovative medicines and

vaccines. Every day, Pfizer colleagues work across developed and emerging

markets to advance wellness, prevention, treatments and cures that challenge

the most feared diseases of our time. Consistent with our responsibility as one

of the world's premier innovative biopharmaceutical companies, we collaborate

with health care providers, governments and local communities to support and

expand access to reliable, affordable health care around the world. For more

than 170 years, we have worked to make a difference for all who rely on us.

SOURCE Pfizer